Study of the Effects of Pre-surgical Aerobic Exercise on Patients With Solid Tumors

Inclusion Criteria:

Phase 0 (Proof-of-Concept)

- Early-stage breast cancer having completed participation in IRB# 15-147 or diagnosed
with the prespecified solid tumors: endometrial, breast and prostate cancer

- Age >18 years

- BMI ≤ 35

- At least a 2-week window from study enrollment to scheduled surgical resection (for
preoperative patients only)

- Performing less than 90 minutes of structured moderate-intensity or
strenuous-intensity exercise per week, as evaluation by self report5

- Access to an email address or MSK portal

- Cleared for exercise participation as per screening clearance via PAR-Q+

- Willingness to comply with all study-related procedures

Phase 1a (Dose-Finding/Escalation) and Phase 1b (Dose-Expansion)

- Patients with operable untreated endometrial, breast or prostate cancer scheduled for
surgery

- Availability of adequate FFPE tumor slides from the diagnostic biopsy to conduct
biological activity and DNA IMPACT panel sequencing

- All other eligibility criteria are identical to those described for Phase 0

Exclusion Criteria:

- Use of any selective estrogen receptor modulator or aromatase inhibitor within 6
months of study entry, including, but not limited to: tamoxifen, raloxifene,
arzoxifene, acolbifene, anastrozole, exemestane, and letrozole (for preoperative
patients only)

- Enrollment onto any other interventional investigational study

- Men receiving GNRH agonists and antagonists as well as any antiandrogrens

- Any neoadjuvant anticancer treatment of any kind

- Any other current diagnosis of invasive cancer of any kind

- Metastatic malignancy of any kind

- Any other condition or intercurrent illness that, in the opinion of the investigator,
makes the subject a poor candidate for study participation.